RVMD
$99.13
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Recent News
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum
Revolution Medicines stock reaction Revolution Medicines (RVMD) has drawn attention after recent trading moves, with the stock closing at $98.40. Investors are weighing this price in relation to its clinical stage oncology profile and current financial metrics. See our latest analysis for Revolution Medicines. While the latest 1 day share price return of 1.24% and 7 day share price return of 3.55% show some recent softness, the 90 day share price return of 22.91% sits alongside a 1 year total...
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact
Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.